LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $94.57 Consensus PT from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $94.57.

Several equities analysts recently commented on LMAT shares. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities increased their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Cantor Fitzgerald began coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, Barrington Research lifted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is currently owned by company insiders.

Institutional Trading of LeMaitre Vascular

Large investors have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co lifted its position in shares of LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after acquiring an additional 6,875 shares during the period. Sequoia Financial Advisors LLC bought a new stake in LeMaitre Vascular in the second quarter valued at $1,010,000. Janus Henderson Group PLC raised its holdings in shares of LeMaitre Vascular by 554.7% during the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock valued at $3,697,000 after purchasing an additional 47,218 shares during the period. Harbor Capital Advisors Inc. boosted its position in shares of LeMaitre Vascular by 240.2% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier’s stock worth $929,000 after purchasing an additional 7,976 shares in the last quarter. Finally, Townsquare Capital LLC grew its stake in shares of LeMaitre Vascular by 38.0% in the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after buying an additional 13,210 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $106.99 on Thursday. LeMaitre Vascular has a 52-week low of $51.70 and a 52-week high of $109.58. The firm has a market cap of $2.41 billion, a price-to-earnings ratio of 58.46, a PEG ratio of 2.59 and a beta of 0.89. The business’s fifty day moving average is $95.52 and its 200-day moving average is $87.96.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.33 earnings per share. As a group, research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be paid a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.60%. LeMaitre Vascular’s payout ratio is 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.